UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

The New England journal of medicine, 2014-06, Vol.370 (25), p.2377-2386

2014

Volltextzugriff (PDF)

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

The New England journal of medicine, 2012-08, Vol.367 (6), p.508-519

2012

Volltextzugriff (PDF)

Sex differences in rheumatoid arthritis: more than meets the eye

BMC medicine, 2009-03, Vol.7 (1), p.12-12, Article 12

van Vollenhoven, Ronald F

2009

Volltextzugriff (PDF)

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years

Journal of rheumatology, 2015-10, Vol.42 (10), p.1761-1766

2015

Volltextzugriff (PDF)

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

Annals of the rheumatic diseases, 2012-08, Vol.71 (8), p.1343-1349

2012

Volltextzugriff (PDF)

Treatment of rheumatoid arthritis: state of the art 2009

Nature reviews. Rheumatology, 2009-10, Vol.5 (10), p.531-541

van Vollenhoven, Ronald F

2009

Volltextzugriff (PDF)

Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?

Arthritis research & therapy, 2015-08, Vol.17 (1), p.181-181, Article 181

2015

Volltextzugriff (PDF)

Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials

Arthritis & rheumatology (Hoboken, N.J.), 2013-08, Vol.65 (8), p.2143-2153

2013

Volltextzugriff (PDF)

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial

The Lancet (British edition), 2014-01, Vol.383 (9914), p.321-332

2014

Volltextzugriff (PDF)

Integrated safety in tocilizumab clinical trials

Arthritis research & therapy, 2011-01, Vol.13 (5), p.R141-R141

2011

Volltextzugriff (PDF)

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

The Lancet (British edition), 2012, Vol.379 (9827), p.1712-1720

2012

Volltextzugriff (PDF)

Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long‐Term Clinical Trial Safety Data in Rheumatoid Arthritis

Arthritis & rheumatology (Hoboken, N.J.), 2017-09, Vol.69 (9), p.1751-1761

2017

Volltextzugriff (PDF)

Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Multiple Intravenous, Dose‐Ascending Study of Sirukumab in Cutaneous or Systemic Lupus Erythematosus

Arthritis & rheumatology (Hoboken, N.J.), 2013-10, Vol.65 (10), p.2661-2671

2013

Volltextzugriff (PDF)

Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study

BMC medicine, 2012-08, Vol.10 (1), p.82-82, Article 82

2012

Volltextzugriff (PDF)

Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial

Annals of the rheumatic diseases, 2015-06, Vol.74 (6), p.1102-1109

2015

Volltextzugriff (PDF)

The association between lupus serology and disease outcomes: A systematic literature review to inform the treat-to-target approach in systemic lupus erythematosus

Lupus, 2022-03, Vol.31 (3), p.307-318

2022

Volltextzugriff (PDF)

Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials

Journal of rheumatology, 2010-03, Vol.37 (3), p.558-567

2010

Volltextzugriff (PDF)

Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay

Science translational medicine, 2019-01, Vol.11 (477)

2019

Volltextzugriff (PDF)

Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study

Rheumatology (Oxford, England), 2012-12, Vol.51 (12), p.2204-2214

2012

Volltextzugriff (PDF)

Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: Studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus

Arthritis & rheumatology (Hoboken, N.J.), 2012-05, Vol.64 (5), p.1579-1588

2012

Volltextzugriff (PDF)

Treatment Algorithms in Systemic Lupus Erythematosus

Arthritis care & research (2010), 2015-09, Vol.67 (9), p.1237-1245

2015

Volltextzugriff (PDF)

Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials

PloS one, 2016-06, Vol.11 (6), p.e0157961-e0157961

2016

Volltextzugriff (PDF)

Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration

Arthritis research & therapy, 2016-02, Vol.18 (50), p.50-50, Article 50

2016

Volltextzugriff (PDF)

Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial

Annals of the rheumatic diseases, 2016-02, Vol.75 (2), p.356-361

2016

Volltextzugriff (PDF)

Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review

Lupus science & medicine, 2021-09, Vol.8 (1), p.e000542

2021

Volltextzugriff (PDF)

1 – 25 von 215

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(199)
Mit Volltextzugriff
(167)

Publikationsform

Artikel
(215)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(209)
Science & Technology
(200)
Life Sciences & Biomedicine
(199)
Rheumatology
(163)
Medicin Och Hälsovetenskap
(157)
Female
(128)
Arthritis, Rheumatoid - Drug Therapy
(117)
Male
(113)
Middle Aged
(100)
Rheumatoid Arthritis
(92)
Adult
(88)
Treatment Outcome
(85)
Antirheumatic Agents - Therapeutic Use
(73)
Severity Of Illness Index
(52)
Drug Therapy, Combination
(50)
Biological And Medical Sciences
(47)
Patients
(47)
Aged
(45)
Medical Sciences
(44)
Lupus Erythematosus, Systemic - Drug Therapy
(42)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

Sex differences in rheumatoid arthritis: more than meets the eye

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

Treatment of rheumatoid arthritis: state of the art 2009

Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?

Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial

Integrated safety in tocilizumab clinical trials

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long‐Term Clinical Trial Safety Data in Rheumatoid Arthritis

Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Multiple Intravenous, Dose‐Ascending Study of Sirukumab in Cutaneous or Systemic Lupus Erythematosus

Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study

Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial

The association between lupus serology and disease outcomes: A systematic literature review to inform the treat-to-target approach in systemic lupus erythematosus

Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials

Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay

Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study

Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: Studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus

Treatment Algorithms in Systemic Lupus Erythematosus

Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials

Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration

Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial

Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review

Aktive Filter

Suchergebnisse filtern